FDA New Drug and Biologic Approvals, 2018 Midyear Review

Mary L Windle, PharmD

August 01, 2018

Phenylketonuria: Palynziq (pegvaliase)

Indication: Indicated to reduce blood phenylalanine concentrations in adults with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations >600 μmol/L on existing management.

Mechanism: Pegvaliase is a PEGylated phenylalanine ammonia lyase (PAL) that substitutes for the deficient phenylalanine hydroxylase (PAH) enzyme activity in patients with PKU, thereby reducing blood phenylalanine concentrations.

Dosage:

Induction: 2.5 mg SC once weekly for 4 weeks
Titration: Based on tolerability, titrate dose in a stepwise manner over at least 5 weeks, to achieve a dosage of 20 mg SC once daily; additional time may be needed for dose escalation depending on tolerability.
Maintenance: Maintain at 20 mg SC once daily for at least 24 weeks; may increase, but should not exceed 40 mg/day in patients who have been maintained continuously on 20 mg/day for at least 24 weeks and who have not achieved a 20% reduction in blood phenylalanine concentration from pretreatment baseline.

Approval was based on two phase 3 studies, PRISM-1 and PRISM-2, which evaluated the efficacy and safety of pegvaliase treatment using an induction, titration, and maintenance dosing regimen in adults with PKU. Of 261 participants who received pegvaliase, 72% and 32.6% reached ≥12 months and ≥ 24 months of study treatment, respectively, and 65% are still actively receiving treatment. Mean (SD) blood Phe was 1232.7 (386.4) μmol/L at baseline, 564.5 (531.2) μmol/L at 12 months, and 311.4 (427) μmol/L at 24 months, a decrease from baseline of 51.1% and 68.7%, respectively.

Reference:

Thomas J, Levy H, Amato S, et al. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018 May;124(1):27-38. https://www.ncbi.nlm.nih.gov/pubmed/29653686

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Mary L Windle. FDA New Drug and Biologic Approvals, 2018 Midyear Review - Medscape - Aug 01, 2018.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.